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SpectrophotometryAbstract Two simple, precise, rapid and economic spectrophotometric methods have been devel-
oped for simultaneous determination of Carvedilol (CV) and Hydrochlorothiazide (HCT) in bulk
powder and combined dosage form. Method (I) is based on dual wavelength analysis while Method
(II) depends on UV-spectrophotometric determination using Q-analysis (graphical absorbance
ratio) method.
In Method (I), two wavelengths were selected for each drug in such a way that the difference in
absorbance is zero for the second drug. At wavelengths 238 and 248.8 nm HCT has equal absor-
bance values, therefore, these two wavelengths have been used to determine CV, on similar basis
266 and 289.4 nm were selected to determine HCT in the combined formulation. Method (II)
involves the formation of Q-absorbance equation using the respective absorptivity values at
229.2 nm (isoabsorptive point) and 241 nm (kmax of CV). The drugs obey Beer’s Lambert’s law
in the concentration range of 1–10 lg/mL for both CV and HCT (for Method I) and in the range
of 1–10 and 2–10 lg/mL for CV and HCT, respectively (for Method II). The accuracy and precision
were determined and recovery studies conﬁrmed the accuracy of the developed methods that were
carried out following the International Conference on Harmonization (ICH) guidelines. Statistical
comparison of the suggested methods with the reported spectrophotometric one using F and t tests
showed no signiﬁcant difference regarding both accuracy and precision.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hydrochlorothiazide (HCT), Fig. 1, is an ofﬁcial drug in both
British and United States Pharmacopoeias (BP, 2007; USP,
2007), it is a thiazide diuretic used to treat mild to moderate
hypertension, usually in combination with other antihyperten-
sive agents with different mechanisms of action (Wellington
and Faulds, 1998). HCT is chemically designated as (6-
chloro-3,4-di hydro-2H-1,2,4-benzothiadiazine-7-sulfon-
S356 N.S. Abdelwahabamide1,1-dioxide) (Budavari, 2002). Carvedilol (CV), Fig. 2, is
an ofﬁcial drug in British and European Pharmacopoeias (BP,
2007; European Pharmacopoeia, 2001), it is an antagonist of
a1 and b1, b2 membrane adrenoceptors and also a modulator
of cardiac electrophysiological properties via interaction with
K+ and Ca2+ ion channels (Karle et al., 2001; Chen and Shih,
2003; Franciosa et al., 2004). It is chemically designated as 1-
(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy) ethyl] ami-
no]-2-propanol (Budavari, 2002). CV is administered alone
or together with antihypertensive, diuretic HCT. Combined
therapy of CV and HCT had a signiﬁcantly greater blood pres-
sure reduction than with the same dosage of the drug alone
(Radevski et al., 1999).
Literature survey revealed that two RP-HPLC methods
were reported for determination of the binary mixture in tablet
dosage form (Sultan, 2008; Haggag et al., 2010). Only one
method has been reported for estimation of the studied drugs
in combined formulation by ﬁrst derivative spectrophotomet-
ric method (Sultan, 2008). But so far no spectrophotometric
method has been reported for simultaneous determination of
CV and HCT in combination; hence an attempt has been made
to develop simple, sensitive, rapid, precise, accurate and eco-
nomic methods to analyze the studied drugs simultaneously
by two spectrophotometric methods, dual wavelength and Q-
analysis methods. The proposed methods have been optimized
and validated as per the International Conference on Harmo-
nization (ICH) guidelines ICH, 2005 and were found to com-
ply with the acceptance criteria.
2. Experimental
2.1. Instruments
Double beam UV–Vis spectrophotometer (Shimadzu, kyoto,
Japan), model UV-1601 PC with 1 cm quartz cells, connected
IBM compatible computer. The bundled software, UV-PC
personal spectroscopy software version 3.7 was used, the spec-Figure 1 Chemical structure of HCT.
Figure 2 Chemical structure of CV.tral band is 2 nm and scanning speed is 2800 nm/min with
0.1 nm interval.
2.2. Chemicals and reagents
1. Pharmaceutical grade CV was obtained as a gift by
Deltapharma S.A.E., Tenth of Ramadan city, A.R.E. It
was certiﬁed to contain 98.75% according to the company
analysis certiﬁcates.
2. Pharmaceutical grade HCT was obtained as gift by Amriya
Pharmaceutical Industries, Alexandria, Egypt. It was certi-
ﬁed to contain 98.5% according to the manufacturer’s
method.
3. Methanol and HCl were purchased from (El-NASR Phar-
maceutical Chemicals Co., Abu-Zabaal, Cairo, Egypt).
HCl (0.1N) aqueous solution was laboratory prepared.
2.3. Marketed formulation
Codilatrol tablets (Batch No. 070140A), is labeled to contain
25 mg CV and 12.5 mg of HCT, manufactured by Chemip-
harm Pharmaceutical industries S.A.E. 6th October-Egypt,
and purchased from the local market.
2.4. Solutions
Standard stock solutions each containing 1000 lg/mL of CV
and HCT were prepared separately in methanol. Working
standard solutions of these drugs (100 lg/mL) were obtained
by dilution of the respective stock solutions in methanol.3. Procedure
3.1. Spectral characteristics and wavelength selection
The absorption spectra of 8 lg/mL each of CV, HCT and their
1:1 mixture (containing 4 lg/mL of each) in 0.1N HCl were
recorded over the range 200–350 nm using 0.1N HCl as blank.
The overlain spectra were observed for selection of the suitable
wavelengths for each of the developed methods, Fig. 3.
3.2. Linearity
3.2.1. Method I (Dual wavelength method)
Standard solutions of both CV and HCT in the range of
1–10 lg/mL were separately prepared by appropriate dilutions
of their respective working standard solutions in 0.1N HCl and
then were scanned in the range of 200–350 nm. Absorbance
values at both 238 and 248.8 nm (for CV) and at both 266
and 289.4 nm (for HCT) were measured. CV was determined
by plotting the difference in absorbance at 238 and 248.8 nm
(difference is zero for HCT) against its corresponding concen-
tration. Similarly for determination of HCT, the difference in
absorbance at 266 and 289.4 nm (difference is zero for CV)
was plotted against the corresponding concentration. The con-
centrations of the two drugs were calculated each from the cor-
responding calibration curve equation.
Figure 3 Zero-order absorption spectra of 8 lg/mL of each of Carvedilol (––), Hydrochlorothiazde (- - -) and 1:1 mixture (. . .. . .)
contains 4 lg/mL of each using 0.1N HCl as a blank.
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Standard solutions containing 1–10 lg/mL each of CV and
HCT were prepared separately using 0.1N HCl. The absorp-
tion spectra of the prepared solutions were recorded in the
range of 200–350 nm and the absorbance values at 229.2 nm
(kiso) and 241 nm (kmax of CV) were measured from which
the absorptivity values for both drugs at the selected wave-
lengths were calculated. The method employs Q values and
the concentrations of the studied drugs in the prepared solu-
tions were determined by using the following equations:
Cx ¼ ½Qm Qy=Qx Qy A=Ax
Cy ¼ ½Qm Qx=Qy Qx A=Ay
where Cx and Cy are the concentrations of CV and HCT in
lg/mL, respectively; Qm is the absorbance of sample at
k229.2/absorbance of sample at k241; Qx is the absorptivity of
CV at k241/absorptivity of CV at k229.2; Qy is the absorptivity
of HCT at k241/absorptivity of HCT at k229.2; Ax is the absorp-
tivity of CV at k229.2; Ay is the absorptivity of HCT at k229.2;
and A is the absorbance of the sample at k229.2.
3.3. Analysis of laboratory prepared mixtures
Different laboratories prepared mixtures containing different
ratios of CV and HCT.. Zero order absorption spectra of these
mixtures were recorded using 0.1N HCl as a blank and then
the differences in absorbance at 238, 248.8 and at 266,
289.4 nm (for Method I) were measured, also the absorbance
values at 229.2 and 241 nm (for Method II) were recorded.
From the calculated regression equations, concentrations of
CV and HCT in the prepared mixtures were calculated.
3.4. Analysis of the marketed formulation
Ten Codilatrol tablets were weighed and crushed to obtain a
ﬁne powder. An accurately weighed tablets powder equivalent
to 100 mg CV and 50 mg HCT was transferred into 100-mLcalibrated measuring ﬂask, 75 mL methanol was added. The
prepared solution was sonicated for 45 mins; the volume was
completed with methanol and the solution was then ﬁltered.
The ﬁltrate was appropriately diluted with methanol to pre-
pare a working solution equivalent to 0.1 mg/mL CV and
0.05 mg/mL HCT. The prepared working solution was further
diluted with 0.1N HCl to get a solution containing 8 lg/mL of
CV and 4 lg/mL of HCT. The prepared mixture was analyzed
and the absorbance values at the selected wavelengths were
determined and the methods given under analysis of labora-
tory prepared mixtures were followed.
3.4.1. Recovery studies
To study the accuracy of the proposed methods, recovery stud-
ies were carried out by standard addition method at different
levels (80%, 100% and 120%). Known amounts of the studied
drugs were separately added to the pre-analyzed tablets pow-
der and the percentage recoveries were calculated.4. Results and discussion
Development of simple, rapid, sensitive and accurate analyti-
cal methods for routine quantitative determination of samples
will reduce unnecessary tedious sample preparations, cost
materials and laboratories. UV-spectrophotometric methods
of analysis offer cost effective and time saving alternative to
HPLC method of analysis (Laxman et al., 2010).
As shown in Fig. 3, zero order absorption spectra of CV
and HCT show strong spectral overlap which interfere with di-
rect spectrophotometric analysis of the studied drugs without
derivatization. On the other hand, the suggested dual wave-
length and Q-analysis methods provide a simple, rapid, conve-
nient and accurate way for simultaneous analysis of CV and
HCT in their combined dosage form without derivatization
procedure.
The main step in the development and validation of an ana-
lytical method of analysis is to improve the conditions and
Table 1 Linear regression and analytical parameters of the proposed methods for determination of Carvedilol and
Hydrochlorothiazide.
Parameters Dual wavelength method Q-analysis method
CV HCT CV HCT
k (nm) Diﬀerence in absorbance
between 238 and 248.8 nm
Diﬀerence in absorbance
between 266 and 289.4 nm
229.2 nm (kiso) and 241 (kmax)
Beer’s law range 1–10 lg/mL 1–10 lg/mL 2–10 lg/mL
Regression
equation
Y = 0.0401X+ 0.0027 Y = 0.0449X  0.0006 C = (Qm  0.0805/
1.3294  0.0805) · A/0.085
C = (Qm  1.3294/
0.0805 – 1.3294) · A/0.087
Correlation
coeﬃcient
0.9999 0.9998 – –
Precision
Repeatability 1.57 1.30 0.89 1.48
Intermediate
precision
0.87 1.15 1.41 0.98
LOD 0.33 lg/mL 0.33 lg/mL 0.20 lg/mL 0.37 lg/mL
LOQ 1 lg/mL 1 lg/mL 0.61 lg/mL 1.10 lg/mL
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validation (Singh et al., 2011). Different solvents were studied
(methanol, ethanol, acetonitrile, water, 0.1N HCl and 0.1N
NaOH) to develop suitable methods of analysis, the criteria
employed were the sensitivity of the method, availability and
toxicity of the solvent. From a solvent effect studies and spec-
tral behaviors of CV and HCT, 0.1N HCl was selected as a sol-
vent for the two suggested methods.
4.1. Dual wavelength method
The principle for dual wavelength method is that the absor-
bance difference at two points on the spectra is directly pro-
portional to the component of interest, independent of the
interfering component (Laxman et al., 2010; Davidson et al.,
2001; Abdel-Aziz et al., 2002; Zahran et al., 2007; Rajesh
et al., 2010a,b). It can be utilized to a great extent without
much complication to calculate the unknown concentration
of the component of interest in a mixture. The pre-requisite
for dual wavelength method is the selection of two such wave-
lengths where the interfering component shows the same
absorbance while the component of interest shows signiﬁcant
difference in absorbance with concentration (Jyotesh et al.,
2010).
As per spectra in Fig. 3 we found that absorption values of
HCT were the same at 238 and 248.8 nm, so that these wave-
lengths were selected for the determination of CV. The same
as in 266 and 289.4 nm, the absorbance values of CV were
the same and hence those two wavelengths were selected for
estimation of HCT. Calibration curves for CV and HCT were
plotted between the absorbance difference at the selected wave-
lengths for each drug and the respective concentration. The two
drugs obeyed Beer’s Lambert’s law in the concentration range
of 1–10 lg/mL with good correlation coefﬁcients, Table 1.
The equations of lines obtained to determine the concentrations
of CV and HCT are as follow:
A1 ¼ 0:0401CCV þ 0:0027 ð1Þ
A2 ¼ 0:0449CHCT  0:0006 ð2Þ
where A1 = the absorbance difference at 238 and 248.8 nm; A2
is the absorbance difference at 266 and 289.4 nm; CCV is theconcentration of CV in lg/mL; and CHCT is the concentration
of HCT in lg/mL.
4.2. Q-analysis (graphical absorbance ratio) method
This method depends on the property that for the substance
that obeys Beer’s Lambert’s law at all wavelengths, the ratio
of absorptivity (or absorbance) values at any two wavelengths
are constant, independent of the concentration or path length.
This ratio is referred as Q-ratio (Bhusari et al., 2009; Wankh-
eda et al., 2009). One of the two selected wavelengths is an iso-
absorptive point and the other is the wavelength of maximum
absorption of one of the two components (Davidson et al.,
2001; Rajesh et al., 2010a,b; Nagulwar and Bhusari, 2010;
Devi and Ramakrishna, 2010; Patil et al., 2009).
From the overlain spectra of the two drugs and their mix-
ture, Fig. 3, it is evident that CV and HCT show isoabsorptive
points at 229.2 and 317.4 nm, CV has kmax at 241 nm while
HCT has kmax at 271 nm. Using the absorbance values at
229.2 nm (kios) and 241 nm (kmax for CV) gave the best results
regarding selectivity. The absorbance values at 229.2 and
241 nm for CV in the range of 1–10 lg/mL were obtained
and similarly for HCT absorbance values in the range of 2–
10 lg/mL were measured, absorptivity coefﬁcients were deter-
mined for both drugs and the average values were taken. The
values and the absorbance ratio were used to develop the fol-
lowing sets of equations from which the concentration of each
component in the sample can be calculated:
CCV ¼ ðQm 0:0805=1:3294 0:0805Þ A=0:085 ð3Þ
CHCT ¼ ðQm 1:3294=0:0805 1:3294Þ A=0:087 ð4Þ
where CCV is the concentrations of CV in lg/mL; CHCT is the
concentrations of HCT in lg/mL; Qm is the absorbance of
sample at k229.2/absorbance of sample at k241; and A is the
absorbance of the sample at k229.2.
To test the selectivity of developing dual wavelength and Q-
analysis methods, they were applied for analysis of number of
laboratory prepared mixtures containing CV and HCT in dif-
ferent ratios. The good percentage recoveries and low SD val-
ues shown in Table 2, conﬁrming the high selectivity of the
suggested methods. The proposed methods have been success-
Table 2 Determination of the studied drugs in the laboratory prepared mixtures (L.P.), pharmaceutical preparations by the proposed
methods and statistical comparison with the reported spectrophotometric method.
Parameters Dual wavelength method Q-analysis method Reported method a
CV HCT CV HCT CV HCT
Accuracy 99.96 ± 0.490 100.03 ± 1.157 99.46 ± 1.485 100.22 ± 1.257 100.41 ± 0.694 99.91 ± 0.961
L.P. mixturesb 100.50 ± 0.915 102.00 ± 0.465 101.20 ± 1.312 100.32 ± 1.093
Codilatrol tabletsc (B.N. 070140A) 96.34 ± 0.446 92.45 ± 0.777 96.46 ± 0.597 92.04 ± 0.797
Standard additionb 101.89 ± 0.840 100.25 ± 1.190 102.09 ± 0.744 98.11 ± 0.862
F-test (6.388)d 2.005 1.448 4.577 1.709
Student’s t-test (2.306)d 1.184 0.184 1.304 0.432
a First derivative spectrophotometric determination of HCT at 285 nm and CV at 248 nm using CH3OH as a solvent.
b Average of three determinations.
c Average of six determinations.
d The values in the parenthesis are the corresponding theoretical values at p= 0.05.
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powder as well as in their combined dosage form. The results
obtained upon using the suggested methods for analysis of CV
and HCT in Codilatrol tablets, Table 2, showed good agree-
ment between the amounts estimated and those claimed by the
manufacturer. Moreover, results obtained by the suggested
methods showed no signiﬁcant difference when compared with
those obtained by applying the reported spectrophotometric
one (Sultan, 2008) as conﬁrmed from F and t values presented
in Table 2. The developing methods have advantages over the
reported one on being more simple, rapid, economic and can
be used for simultaneous determination of the two studied
drugs without derivatization or sample pre-treatment.
4.3. Methods validation
Methods validation has been performed as per the Interna-
tional Conference on Harmonization (ICH) guidelines ICH,
2005 and USP requirements (The United States Pharmacopeia,
2007).
4.3.1. Linearity
The linearity of the developed methods was evaluated by ana-
lyzing different concentrations of standard solutions of CV
and HCT in triplicates. For dual wavelength method, Beer’s
Lambert’s concentration range was found to be 1–10 lg/mL
for both CV and HCT. On the other hand, for Q-analysis
method the range of CV was found to be 1–10 lg/mL while
for HCT was found to be 2–10 lg/mL. The values of correla-
tion coefﬁcients were close to unity indicating good linearity,
the characteristic parameters for the constructed equations
are summarized in Table 1.
4.3.2. Speciﬁcity
The speciﬁcity of the proposed methods was assessed by their
application to the analysis of laboratory prepared mixtures
containing different ratios of intact CV and HCT. Satisfactory
results were obtained and presented in Table 2, conﬁrming that
each of the cited drugs could be successfully determined with-
out interference from the other.
4.3.3. Accuracy
Accuracy was calculated as the percentage recoveries of blind
samples of pure CV and HCT and it indicated the agreement
between obtained results and those accepted as true, detailedresults are presented in Table 1. To ascertain the accuracy of
the suggested methods, recovery studies were carried out by
standard addition technique at three different levels (80%,
100% and 120%). Percentage recoveries for CV and HCT by
both the two methods were found to be acceptable, Table 2.
4.3.4. Precision
Precision was assessed as RSD% at different levels; repeatabil-
ity was evaluated by the analysis of three different concentra-
tions of pure drugs (3, 6 and 8 lg/mL) for each in triplicates on
the same day and intermediate precision by repeating analysis
of the same concentrations of each seven times on four consec-
utive days. The results of intra-day and inter-day precision
conﬁrmed the precision of the proposed methods, Table 1.
4.3.5. Limits of detection (LOD) and quantitation (LOQ)
They were calculated from the standard deviation (d) of the re-
sponse and the slope of the calibration curve (S) in accordance
to the following equations: LOD= 3.3 (d/S) and LOQ= 10
(d/S). Results presented in Table 1, indicated that the method
is sensitive for determination of the studied drugs.5. Conclusion
The developed dual wavelength and Q-analysis spectrophoto-
metric methods have been successfully applied for simulta-
neous determination of CV and HCT in combined sample
solution, they were found to be rapid, simple, sensitive and
accurate. Once the equations were constructed, analysis re-
quired only measuring the absorbance values of the sample
solution at the selected wavelengths followed by few simple
calculations. The suggested methods were completely validated
showing satisfactory data for all the method validation param-
eters tested. Recovery studies indicated that practically there
was no interference from tablet additives, so these methods
can be easily and conveniently adopted for routine quality con-
trol analysis of CV and HCT.References
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